LAMC2 Antibody

What is the molecular structure and cellular localization of LAMC2?

LAMC2 is a subunit of laminin-332 (previously known as laminin-5), with a canonical length of 1193 amino acid residues and a mass of approximately 131 kDa in humans . It exists primarily in the extracellular matrix and is secreted, with two different isoforms reported . In Western blot applications, LAMC2 can be detected at 140 kDa (full-length form) and at 100 kDa and 80 kDa (representing endogenously cleaved forms) . Immunofluorescence studies demonstrate strong cytoplasmic localization in various cell lines, particularly in cancer cells like HTH83, TL3, SW1736, and CAL62 .

What are the primary biological functions of LAMC2 in normal tissue physiology?

LAMC2 plays essential roles in multiple physiological processes:

• Mediates cell attachment, migration, and organization into tissues during embryonic development by interacting with extracellular matrix components

• Contributes to basement membrane stability and tissue organization

• Actively participates in wound healing by promoting keratinocyte migration and melanin transport

• Exhibits cell-scattering activity toward various cell types including epithelial, endothelial, and fibroblastic cells

• Functions in cell adhesion and epidermis development through specialized interactions with surface receptors

What criteria should researchers consider when selecting a LAMC2 antibody?

When selecting a LAMC2 antibody, researchers should consider:

• Antibody Type: Options include recombinant monoclonal (e.g., EPR23654-127), traditional monoclonal (e.g., CL2980, D7, 5H2), and polyclonal antibodies

• Target Epitope: Antibodies targeting different regions (e.g., within aa 400-650) may have different specificities

• Validated Applications: Verify that the antibody has been validated for your specific application (WB, IHC, ICC/IF, ELISA, IP, Flow Cytometry)

• Species Reactivity: Most LAMC2 antibodies target human proteins, with variable cross-reactivity to mouse and rat orthologs

• Publication Record: Consider antibodies cited in peer-reviewed publications for your application

How can researchers validate LAMC2 antibody specificity?

To ensure antibody specificity:

• Positive Controls: Use cell lines known to express LAMC2 (A431, A549, lung squamous cell carcinoma)

• Knockdown Validation: Compare staining between LAMC2-silenced cells and control cells

• Multiple Detection Methods: Confirm expression using alternative techniques (e.g., RT-PCR with Western blot)

• Predicted vs. Observed Bands: Verify band sizes match expected molecular weights (140 kDa full-length, 100 kDa and 80 kDa cleaved forms)

• Immunoprecipitation: Perform IP followed by Western blot to confirm specificity

What are the optimal conditions for detecting LAMC2 by Western blot?

For optimal Western blot detection of LAMC2:

• Sample Preparation: Use cell lysates from epithelial-derived cell lines like A431 or lung carcinoma cells

• Antibody Dilution: Typically 1 μg/mL to 1:1000 depending on the specific antibody

• Expected Bands: 140 kDa (full-length), with additional bands at 100 kDa and 80 kDa representing endogenously cleaved forms

• Blocking: 5% non-fat dry milk in TBST is recommended

• Exposure Time: Approximately 41 seconds has been reported as optimal for some antibodies

• Positive Controls: A431 (human epidermoid carcinoma epithelial cell) is an established positive control

How should immunohistochemistry protocols be optimized for LAMC2 detection in tissue samples?

For IHC detection of LAMC2:

• Tissue Fixation: 4% paraformaldehyde fixation is commonly used

• Antibody Concentration: Approximately 10 μg/mL for paraffin-embedded sections

• Positive Control Tissues: Normal human skin, skin cancer, normal breast, and breast adenocarcinoma tissues

• Expected Staining Pattern: Diffuse cytoplasmic staining in positive cells

• Negative Controls: Adjacent non-cancerous tissues (ANCT) typically show little to no expression

• Visualization: Include appropriate secondary antibodies and detection systems compatible with your primary antibody

What methodological approaches can enhance LAMC2 detection in immunocytochemistry?

For ICC/IF applications:

• Cell Fixation: 4% paraformaldehyde followed by 90% methanol permeabilization

• Antibody Dilution: 1:500 dilution (0.1μg) has shown good results

• Cell Lines: A431 and A549 cells have been successfully used

• Expected Pattern: Strong cytoplasmic localization with proper fixation and permeabilization

• Controls: Include isotype control antibodies (e.g., Rabbit monoclonal IgG) and unlabelled controls

• Analysis Method: Flow cytometry can be used to quantify intracellular LAMC2 levels

How is LAMC2 expression altered across different cancer types?

LAMC2 expression varies significantly across cancer types:

• Upregulated in:

  • Anaplastic thyroid carcinoma (70% of specimens show positive diffuse cytoplasmic staining)

  • Gastric cancer cell lines compared to normal gastric epithelial cells

  • Cholangiocarcinoma (with highest expression fold change of log ratio 2.7229)

  • Lung, pancreatic, bladder, colorectal, cervical, and squamous cell carcinomas

• Variable Expression:

  • Decreased in some lung, prostate, breast, and basal cell skin carcinomas due to aberrant regulation

  • Expression patterns may vary even within the same cancer type based on histological subtypes

What molecular mechanisms underlie LAMC2's role in cancer progression and metastasis?

LAMC2 promotes cancer progression through several mechanisms:

• Receptor Interactions: Binds to EGFR in cancer cells, as demonstrated by immunoprecipitation studies

• Signaling Pathway Activation: Activates PI3K/Akt pathway and promotes EMT

• Gene Expression Regulation: Alters expression of genes associated with migration, invasion, proliferation, and survival

• EMT Acceleration: Decreases E-cadherin expression while increasing Vimentin levels

• Cell Cycle Regulation: LAMC2 knockdown causes cell cycle arrest in cancer cell lines

• Growth Factor Signaling: Partially mediates EGF-induced activation of EGFR and downstream pathways

How does LAMC2 silencing affect cancer cell behavior in experimental models?

LAMC2 knockdown studies reveal significant effects on cancer cells:

• In Vitro Effects:

  • Moderate inhibition of cell growth in liquid culture

  • Dramatic decrease in anchorage-independent growth in soft agar

  • Suppressed migration, invasion, and wound healing capabilities

  • Cell cycle arrest and altered gene expression

• In Vivo Effects:

  • 75% reduction in tumor weight in xenograft models after 30 days

  • Decreased Ki-67 staining (proliferation marker) in tumor tissues

  • Reduction in CD31-positive blood vessels, suggesting anti-angiogenic effects

  • Rescue experiments with LAMC2 overexpression reverse these inhibitory effects

How can LAMC2 serve as a prognostic biomarker in cancer research?

Research demonstrates LAMC2's potential as a prognostic biomarker:

What is the relationship between LAMC2 and EGFR signaling in cancer?

LAMC2-EGFR interaction represents a significant cancer mechanism:

• Physical Interaction: Immunoprecipitation studies demonstrate LAMC2 binding to EGFR in cancer cells

• Signaling Modulation: LAMC2 silencing partially blocks EGF-mediated activation of EGFR and downstream pathways

• Therapeutic Implications: Suggests potential for combination therapies targeting both LAMC2 and EGFR pathways

• Feedback Mechanisms: Potential bidirectional regulation between LAMC2 expression and EGFR signaling

• Cancer Type Specificity: This interaction may have different significance across cancer types

How do post-translational modifications affect LAMC2 function in normal versus malignant contexts?

Post-translational modifications of LAMC2 have significant functional implications:

• Glycosylation: O-glycosylation affects LAMC2 stability and interactions with cell surface receptors

• Proteolytic Processing: Generates fragments with distinct biological activities (observed as 140 kDa, 100 kDa, and 80 kDa bands)

• Cancer-Associated Changes: Altered glycosylation and proteolytic processing may contribute to cancer progression

• Detection Implications: Different antibodies may preferentially detect specific modified forms

• Therapeutic Targeting: Specific modifications might represent novel therapeutic targets

What are common challenges in LAMC2 antibody-based experiments and their solutions?

Researchers face several challenges when working with LAMC2 antibodies:

• Specificity Issues:

  • Solution: Validate using multiple antibodies targeting different epitopes

  • Confirm specificity using knockdown/knockout controls

• Variable Band Patterns:

  • Solution: Understand the expected pattern (140 kDa full-length, 100 kDa and 80 kDa cleaved forms)

  • Use positive control lysates with established band patterns

• Weak Signal:

  • Solution: Optimize antibody concentration (typically 1 μg/mL to 1:1000 for WB)

  • Improve extraction methods for extracellular matrix proteins

• Background in IHC/ICC:

  • Solution: Optimize blocking (5% NFDM/TBST recommended)

  • Include appropriate negative controls (isotype antibodies)

How should researchers approach detection of secreted versus cellular LAMC2?

Detecting different LAMC2 pools requires specialized approaches:

• Cellular LAMC2:

  • Standard cell lysis protocols with attention to membrane protein extraction

  • ICC/IF with appropriate fixation and permeabilization

• Secreted LAMC2:

  • Collection and concentration of conditioned media

  • ELISA-based detection using validated antibodies (5 μg/mL)

  • Analysis of Lm332-expressing cell condition medium

• Combined Analysis:

  • Parallel analysis of cell lysates and conditioned media

  • Fractionation approaches to separate membrane-associated from secreted forms

  • Correlation with in vivo expression patterns